



Newsletter

March 2026

Dear EuroSIDA Study Investigators,

The EuroSIDA Coordinating Centre sends warm winter greetings to all our collaborators. We deeply appreciate your ongoing commitment to the study. Below, we would like to share a few updates with you.

Study Updates

Dataset 53

Dataset 53 opened on 1 September 2025 for REST sites and on 1 October 2025 for REDCap sites. The original deadline for data submission was 1 December 2025, with a limited extension granted to a small number of sites to allow completion of the remaining follow-up forms. We thank all participating sites for their continued support and flexibility during this data collection round.

Follow-up closed on **2 January 2026**. Approximately **8,900 of 9,200 EuroSIDA FU53** forms have been completed in **REDCap**, and **EuroSIDA REST FU53 data** have been received from approximately **2,000 participants**. Data were submitted by 74 sites, while 5 sites did not deliver data.

The data cleaning and download process is ongoing and we expect a final dataset ready for analyses in July.

EuroSIDA Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) Enrolments

A new cohort investigating uptake and outcomes of LA CAB+RPV was initiated with the support of ViiV Healthcare and the EuroSIDA Steering Committee, with first enrolment November 2024. To date, **740 new participants** have been enrolled from 28 EuroSIDA sites across 13 countries, with the highest enrolments from **Belgium, Spain, Italy, Netherlands, Germany, and Poland**. We thank all contributing sites for their continued efforts and support

as we work towards reaching the target of 750 enrolments. Enrolment will remain open until **31 July 2026**.

However, it will close earlier if the target number of participants is reached.

We kindly remind sites to ensure that all injection dates are entered in the short REDCap form. We strongly encourage completion of these forms in real time to ensure optimal data quality.

Important Update to EuroSIDA Study Procedures

As previously communicated by email, changes to EuroSIDA procedures will take effect due to reduced funding for cohort research in the coming years. The EuroSIDA Steering Committee approved the following changes on 26 June 2025:

- Discontinuation of plasma sample collection from **1 August 2025**. Reimbursement will still be provided for samples collected up to this date. *
- Reduction in reimbursement rate for follow-up forms from **20 EUR to 15 EUR** (applies to all EuroSIDA sites). This change requires a contract amendment, and the Coordinating Centre has contacted each site individually regarding this update.

**Please note: These changes do not affect MISTRAL or Cabotegravir FU forms*

We sincerely appreciate your understanding and flexibility in adapting to these changes. If you have any questions or concerns, please don't hesitate to contact the [EuroSIDA Coordinating Centre](#).

MISTRAL

The MISTRAL study included 22 EuroSIDA sites in 11 countries across Europe and Israel. A total of **991** participants have been enrolled (visit 1), of whom 795 have completed the follow-up visit (visit 2). In total, approximately 27,400 samples (stool, plasma, and whole blood) have been collected, including 15,300 samples at visit 1 and 12,100 samples at visit 2.

The final report to the EU has been successfully submitted.

MISTRAL FU3 data have been downloaded and will be available for analysis shortly. The clinical data from FU3 links to the remaining second study visits in 2025 and completes the MISTRAL dataset. The EuroSIDA team is currently developing a data catalogue to provide researchers and EuroSIDA investigators with a clearer overview of the data collected within the MISTRAL study. This resource will support the preparation and submission of study proposals and will be made available on the CHIP website very soon.

For more information on the MISTRAL study [click here](#).

EuroSIDA Steering Committee member

There has been a change in the EuroSIDA Steering Committee representation from Ukraine. Olena Nesterova has withdrawn from her role as a EuroSIDA site representative and from the Steering Committee. **Dr. Serhii Serbokon**, an infectious disease specialist at the Public Health Center, Ministry of Health of Ukraine, Kyiv (June 2018-present), was approved as her replacement at the Steering Committee meeting in January 2026.

RESPOND

EuroSIDA remains the largest contributor of participants in the RESPOND cohort consortium, with approximately 14,000 participants of total 47,000 participants and is represented in the Executive Committee and in the Scientific Steering Committee.

RESPOND presentations in 2026

- **CROI 2026**, Denver, Colorado, USA, 22–25 February 2026:
Poster presentation: Evaluating the Impact of Integrase Inhibitors (InSTIs) on Cardiovascular Disease (CVD) will be presented by Bastian Neesgaard on behalf of the RESPOND Scientific Group.
- **IWHOD 2026**, Thessaloniki, Greece, 26–29 March 2026:
Poster presentation: Risk of Fracture with contemporary antiretrovirals within the RESPOND Consortium will be presented by Bastian Neesgaard on behalf of the RESPOND study group.

For full overview of all RESPOND presentations and publications, please see the RESPOND website, and to stay up to date with ongoing and upcoming research activities, [follow RESPOND on the website](#).

EuroSIDA Investigator Meeting in EACS, October 2025

EuroSIDA and MISTRAL investigator meetings took place during the EACS Conference in Paris on 15 October 2025. It was a pleasure to host this session and to connect in person with our valued collaborators. The meeting featured lively discussions on key topics, including CAB +RPV cohort updates, funding and resource allocation and ongoing study progress across EuroSIDA and MISTRAL. As always, these annual meetings provide an opportunity to share insights, exchange ideas, and strengthen collaboration across our network. A snapshot from the meeting is included below.



We look forward to continuing this tradition at the **HIV Glasgow conference**, which will be held in Glasgow from **8-11 November 2026**. Invitations will be sent to all investigators, and we hope to see you there for another engaging session.

Message from Friends: HepHIV Conference 2026, Dublin

Save the date! HepHIV 2026 will take place on **2-3 November 2026 in Dublin, Ireland!** Read the full HepHIV 2026 newsletter [here](#).



Since 2007, the EuroTEST initiative has organized biennial conferences focused on optimal testing and earlier care. The conference features plenaries, expert panels, roundtable discussions and parallel sessions based on peer-reviewed abstracts.

- The call for abstracts for HepHIV 2026 will open in May 2026.
- The conference programme will be available shortly on [the conference website](#).

If you have any questions related to the conference, please contact the Conference Secretariat at hephiv.rigshospitalet@regionh.dk

Reminders

Data Processing Agreement (DPA)

As plasma sampling has been discontinued from 1 August 2025, we will also cease any ongoing DPA-related procedures.

Regulatory Approvals

We kindly urge you to **keep us informed of any updates** or progress from your respective ethics committees to facilitate the progress.

Staff Changes

Please inform us of any changes in staff or principal investigators at your site. This will allow us to update the study group and database accordingly.

EuroSIDA Publications

The EuroSIDA study has reached **353 publications!**

All EuroSIDA publications can be found [here](#).

EuroSIDA Staff Update

We are delighted to welcome two new colleagues:

Joanne Reekie

We are delighted to welcome back Joanne Reekie, leader of the biostatistician group, to CHIP. Joanne had left in September 2024 to relocate to Australia, and we are thrilled to have her expertise and contributions back on the team. Her return will greatly strengthen our ongoing work and support for the EuroSIDA study.

Julie Laub Erdal

We are pleased to welcome Julie Laub Erdal, a new PhD student in the EuroSIDA and RESPOND cohort group and the new RESPOND study coordinator. Julie is a medical doctor recruited from the department of infectious diseases at Hvidovre Hospital Denmark, and we look forward to her contributions to the cohort team.

We hope everyone in the EuroSIDA study is having a wonderful summer!

Thank you for a continuous rewarding, and successful collaboration.



Contact

Please always feel free to contact the EuroSIDA coordinating centre at eurosidea.rigshospitalet@regionh.dk.

No question is too small or too big, we are happy to assist in all matters!

**EuroSIDA Coordinating Centre
Rigshospitalet
CHIP, Section 2100
Blegdamsvej 9 · Copenhagen 2100 · Denmark**